

## Special Issue

# Targeting the Tumor Microenvironment

### Message from the Guest Editors

The tumor microenvironment (TME) plays a pivotal role in different types of cancer. The interactions that occur within the TME are fundamental in tumor-induced suppression of the immune system and metastatic dissemination of cancer cells, and these mechanisms may ultimately affect tumor progression and treatment outcome. Recently introduced cancer therapies are targeting the interaction between tumors and the TME. However, stromal components of the tumor niche may extensively affect drug response in tumor cells. Furthermore, stroma-targeted strategies have emerged as a new treatment option for many types of cancer. Despite, the recent advancement in cancer treatment a proportion of patients remain resistant, thus, it is necessary to develop innovative therapeutic approaches by investigating the fundamental role of TME. In this Special Issue, “Targeting the Tumor Microenvironment”, authors are invited to contribute cutting-edge studies that will further highlight the involvement of TME in cancer progression and treatment

---

### Guest Editors

Prof. Dr. Georgios Giamas

School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK

Dr. Teresa Gagliano

School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK

---

### Deadline for manuscript submissions

closed (31 January 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/42705](https://mdpi.com/si/42705)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)